Results 1 to 10 of about 28,367 (198)

An Interactive Pharmacokinetic‐Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Bedaquiline is approved for use in a thrice‐weekly dosing schedule; simpler once‐daily dosing strategies could enable fixed‐dose combinations and improve patient adherence.
Yu‐Jou Lin, Frances Okibedi, Mats O. Karlsson, Elin M. Svensson   +3 more
doaj   +3 more sources

Safety of prolonged treatment with bedaquiline in programmatic conditions

ERJ Open Research, 2022
Bedaquiline is now considered a first-line medicine for treatment of rifampicin-resistant tuberculosis (RR-TB). We evaluated the safety of treatment with bedaquiline for longer than 190 days in individuals with RR-TB under programmatic conditions.
Dzmitriy Zhurkin, Elmira Gurbanova, Jonathon R. Campbell, Dick Menzies, Svetlana Setkina, Hennadz Hurevich, Varvara Solodovnikova, Dzmitry Viatushka, Alan Altraja, Alena Skrahina   +9 more
doaj   +2 more sources

Drug-Resistant Tuberculous Spondylitis Treated with Bedaquiline-Containing Regimens in South Korea: Two Case Reports [PDF]

Antibiotics
Background: South Korea continues to report a considerable burden of drug-resistant tuberculosis (TB). Bedaquiline-containing regimens are recommended for multidrug-resistant pulmonary TB, but evidence regarding the optimal treatment for extrapulmonary ...
Keon Young Lee, Miri Hyun, Ji Yeon Lee, Hyun ah Kim   +3 more
doaj   +2 more sources

Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis

BMC Infectious Diseases, 2022
Background This retrospective cohort study assessed benefits and risks of bedaquiline treatment in multidrug-resistant-tuberculosis (MDR-TB) combination therapy by evaluating safety, effectiveness, drug utilization and emergence of resistance to ...
Helen Pai, Norbert Ndjeka, Lawrence Mbuagbaw, Koné Kaniga, Eileen Birmingham, Gary Mao, Lori Alquier, Kourtney Davis, Arianne Bodard, Abeda Williams, Magalie Van Tongel, Florence Thoret-Bauchet, Shaheed V. Omar, Nyasha Bakare   +13 more
doaj   +1 more source

Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis

International Journal of Infectious Diseases, 2021
Objectives: To determine the safety and efficacy of bedaquiline for Chinese patients with multidrug-resistant tuberculosis (MDR-TB) based on serum concentration monitoring and to identify factors associated with QTc prolongation occurring during ...
Jinmeng Li, Gaoyi Yang, Qingshan Cai, Yu Wang, Yingying Xu, Ruoying Zhang, Yazhen Lang, Xinjun Cai   +7 more
doaj   +1 more source

A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea

BMC Infectious Diseases, 2023
Background Multidrug-resistant tuberculosis (MDR-TB) represents a major public health concern, with an ongoing need for new effective treatments. Bedaquiline is an oral diarylquinoline that has shown encouraging treatment success and culture conversion ...
Tae Sun Shim, Helen Pai, JeongHa Mok, Seung Heon Lee, Yong-Soo Kwon, Jae Chol Choi, JaeSeok Park, Eileen Birmingham, Gary Mao, Lori Alquier, Kourtney Davis, Florence Thoret-Bauchet, Ji Hyun Kim, Hyeongyeong Kim, Nyasha Bakare   +14 more
doaj   +1 more source

Tolerability and Efficacy of Chemotherapy Containing Bedaquiline in Patients with Multiple Drug Resistant Pulmonary Tuberculosis

Туберкулез и болезни лёгких, 2022
The objective: to evaluate safety and efficacy of bedaquiline in the treatment of patients with multiple drug resistant tuberculosis (MDR-TB).Subjects and Methods.
O. V. Filinyuk, D. Yu. Schegertsov, N. N. Kabanets, D. E. Amichba   +3 more
doaj   +1 more source

Maleate salts of bedaquiline [PDF]

Acta Crystallographica Section E Crystallographic Communications, 2021
Bedaquiline is one of two important new drugs for the treatment of drug-resistant tuberculosis (TB). It is marketed in the US as its fumarate salt, but only a few salts of bedaquiline have been structurally described so far. We present here five crystal structures of bedaquilinium maleate {systematic name: [4-(6-bromo-2-methoxyquinolin-3-yl)-3-hydroxy ...
Matthias Zeller, Susan Bogdanowich-Knipp, Pamela Smith, Dale K. Purcell, Mercy Okezue, Daniel T. Smith, Stephen R. Byrn, Kari L. Clase   +7 more
openaire   +3 more sources

Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China

International Journal of Infectious Diseases, 2020
Objective: The aim of this study was to investigate the molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis (MTB) isolates from Shaanxi, China.
Jian Yang, Yu Pang, Tianhua Zhang, Xiaoping Xian, Yan Li, Rui Wang, Panting Wang, Meng Zhang, Junyang Wang   +8 more
doaj   +1 more source

Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase

Frontiers in Immunology, 2021
Although bedaquiline has advanced the treatment of multidrug-resistant tuberculosis (TB), concerns remain about the cardiotoxic potential of this agent, albeit by unexplored mechanisms.
Gregory R. Tintinger, Annette J. Theron, Helen C. Steel, Moloko C. Cholo, Jan G. Nel, Jan G. Nel, Charles Feldman, Ronald Anderson   +7 more
doaj   +1 more source